ArrayPlex Selected by Immunome for Targeted Cancer Therapies
Arrayjet’s ArrayPlex™ Platform Has Been Selected by Immunome for Its Discovery of Targeted Cancer Therapies
Overview
Arrayjet, a leading provider of inkjet liquid-handling solutions, has announced that Immunome, Inc. (NASDAQ: IMNM), a biotechnology company focused on developing targeted cancer therapies, has selected its ArrayPlex™ discovery platform to enhance its in-house high-throughput screening capabilities. The ArrayPlex platform, developed by Arrayjet to meet specific assay requirements for high-throughput screening services and tools, will now be accessible to Arrayjet’s screening customers either through its CRO/CMO services or by purchasing an instrument for in-house screening.
Successful Partnership
- During a successful seven-year partnership, Arrayjet utilized the ArrayPlex platform to perform screening services for Immunome.
- Arrayjet has continuously optimized the platform, integrating internal assay controls and enhancing data normalization.
- Immunome's decision to acquire an instrument and internalize the ArrayPlex assay underscores its commitment to advancing cancer therapeutic discovery.
Arrayjet’s Inkjet Technology
- ArrayPlex utilizes Arrayjet’s inkjet technology for bioprinting, enabling the rapid creation of multi-layered assays.
- This approach facilitates screening of two libraries against each other for unique binding interactions, generating hits without prior knowledge of either ligand or target at high-throughput rates.
- The platform is compatible with various sample types and offers sensitivity comparable to or greater than ELISA.
Words from CEO of Arrayjet
Dr. Iain McWilliam, CEO of Arrayjet, expressed satisfaction with the integration of ArrayPlex into Immunome’s in-house operations, highlighting its potential to advance cancer therapeutic discovery for a broader customer base.
